{"id":"https://genegraph.clinicalgenome.org/r/7a092698-c6bf-45f4-a48f-af3b0c7ac1a1v2.0","type":"EvidenceStrengthAssertion","dc:description":"ALPK3 encodes for protein α-kinase 3, an essential cardiac pseudokinase which functions to aid in myosin-mediated force buffering and sarcomere proteostasis. ALPK3 was first reported in relation to autosomal dominant HCM in 2018 (Jaouadi et al., 2018 PMID: 30046096). At least 38 variants (nonsense, frameshift, and splice site) have been reported in probands in five publications (PMIDs: 34263907, 32480058, 30046096, 33191771, 37973666) are included in this curation. Variants in this gene segregate in at least three families. Two case-control studies showed that the proportion of ALPK3 loss-of-function variants in cardiomyopathy cohorts was significantly higher than control cohorts. More evidence is available in the literature, however, the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of disease is loss of function and this gene-disease relationship is supported experimental evidence included biochemical function, expression, and models (PMIDs: 11418590, 36321451, 39196058), reaching the maximum score of 6 with the inclusion of the a recent knock-in mouse model which demonstrated a hypertrophic response following chronic adrenergic challenge, and partial rescue of the cellular phenotype by Mavacamten (Leinhos L, et al., 2024 https://www.biorxiv.org/content/10.1101/2024.09.30.615779v1).  In summary, ALPK3 has a strong association with autosomal dominant HCM; this has been demonstrated in both research and clinical settings. An analysis will be performed separately to determine the strength of evidence for ALPK3 in an autosomal recessive cardiomyopathy. This classification was approved by the ClinGen Hereditary Cardiovascular Disease GCEP on December 19, 2023.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/7a092698-c6bf-45f4-a48f-af3b0c7ac1a1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d","calculatedEvidenceStrength":"Strong","changes":[{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"},{"id":"cg:newEvidence"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10104","date":"2025-01-16T01:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10104","date":"2025-01-19T23:59:32.577Z","role":"Publisher"}],"curationReasons":["RecurationDiscrepancyResolution"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5b7f0d1-a92b-43a1-866a-100559204f22","type":"EvidenceLine","dc:description":"gnomAD: MAF = 0.00004627 in European (Finnish) population; https://gnomad.broadinstitute.org/variant/15-85370828-TC-T","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5b7f0d1-a92b-43a1-866a-100559204f22_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33302605","allele":{"id":"https://genegraph.clinicalgenome.org/r/5dba9249-f84b-43e4-8f0b-d1cf744bca52","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020778.5(ALPK3):c.297del (p.Ile99fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1342709"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/652e3919-7a45-4728-95ce-dabf5eba4158","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/652e3919-7a45-4728-95ce-dabf5eba4158_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32480058","rdfs:label":"Herkert Dutch Case Control","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/606d5cd1-e971-4fec-8c46-08ee8541ba03","type":"Cohort","allGenotypedSequenced":1548,"alleleFrequency":0.0251937984496124,"detectionMethod":"NGS panel (127 genes)","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/652e3919-7a45-4728-95ce-dabf5eba4158_cc_evidence_item"}],"numWithVariant":39,"relatedCondition":{"id":"obo:MONDO_0004994"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/d990fabe-3cfc-4794-9938-4816e1351ea5","type":"Cohort","allGenotypedSequenced":64000,"alleleFrequency":0.033578125,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/652e3919-7a45-4728-95ce-dabf5eba4158_cc_evidence_item"}],"numWithVariant":2149},"lowerConfidenceLimit":0.2,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.000016,"statisticalSignificanceType":"","upperConfidenceLimit":1.07}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4243be58-b446-4f1c-b5c7-2f0935c5cf06","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4243be58-b446-4f1c-b5c7-2f0935c5cf06_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","rdfs:label":"Lopes Discovery Cohort","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/9294abbf-8879-4ec0-99f3-e21037ba8990","type":"Cohort","allGenotypedSequenced":770,"alleleFrequency":0.01558441558441558,"detectionMethod":"WES, variants confirmed by Sanger sequencing","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4243be58-b446-4f1c-b5c7-2f0935c5cf06_cc_evidence_item"}],"numWithVariant":12,"relatedCondition":{"id":"obo:MONDO_0005045"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/d3785cf2-dbc0-473f-bc5b-a1d850b587e7","type":"Cohort","allGenotypedSequenced":75431,"alleleFrequency":0.0009810290198989805,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4243be58-b446-4f1c-b5c7-2f0935c5cf06_cc_evidence_item"}],"numWithVariant":74},"lowerConfidenceLimit":7.94,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":8.05E-11,"statisticalSignificanceType":"","statisticalSignificanceValue":16.11,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":30.02}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c3a355bd-2630-4689-90e1-66c69e2a068a","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3a355bd-2630-4689-90e1-66c69e2a068a_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32480058","rdfs:label":"Herkert US Case Control ","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/04601960-c6fb-4799-bde5-bd6395880450","type":"Cohort","allGenotypedSequenced":149,"alleleFrequency":0.1006711409395973,"detectionMethod":"WES","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3a355bd-2630-4689-90e1-66c69e2a068a_cc_evidence_item"}],"numWithVariant":15,"relatedCondition":{"id":"obo:MONDO_0004994"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/3393d9c3-e399-475b-a196-43e2b0de0a66","type":"Cohort","allGenotypedSequenced":64000,"alleleFrequency":0.001140625,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3a355bd-2630-4689-90e1-66c69e2a068a_cc_evidence_item"}],"numWithVariant":73},"lowerConfidenceLimit":2.69,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":2.2E-13,"statisticalSignificanceType":"","upperConfidenceLimit":11.05}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d5fafe03-a04d-4e21-8a0c-5b5df2e43c91","type":"EvidenceLine","dc:description":"statistics scored compare the HCM cohort (n = 2047) to gnomAD population; Other states provided by case control study: \"Prevalence of ALPK3 variants found in simple heterozygosity was significantly higher in the HCM cohort (32/2047; 1.56%) than in disease control subjects/non-cardiomyopathy controls (1/1059; 0.09%), non-HCM cases (4/2857; 0.14%) and gnomAD database (74/75431; 0.1%), with an OR of 16.8 (95% CI: 2.79–682.77; P = 2.375e−05), 11.32 (95% CI: 4.01–44.09; P = 8.01e−09), and 16.17 (95% CI: 10.31–24.87; P = 2.2e−16), respectively\"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5fafe03-a04d-4e21-8a0c-5b5df2e43c91_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","rdfs:label":"Lopes Validation Cohort","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/5a0826b4-012a-4b11-8538-c23edfc3f637","type":"Cohort","allGenotypedSequenced":4904,"alleleFrequency":0.00734094616639478,"detectionMethod":"NGS of 261 genes related to inherited cardiovascular disease","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5fafe03-a04d-4e21-8a0c-5b5df2e43c91_cc_evidence_item"}],"numWithVariant":36,"relatedCondition":{"id":"obo:MONDO_0004995"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/24b7da16-979d-49e6-8c14-3c6c403e4f19","type":"Cohort","allGenotypedSequenced":75431,"alleleFrequency":0.0009810290198989805,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5fafe03-a04d-4e21-8a0c-5b5df2e43c91_cc_evidence_item"}],"numWithVariant":74},"lowerConfidenceLimit":2.79,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.0000237,"statisticalSignificanceType":"","statisticalSignificanceValue":16.8,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":682.77}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/236601c9-e0d2-4a62-a4ba-20e01e138244","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/236601c9-e0d2-4a62-a4ba-20e01e138244_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5e4b7be-990b-4aa2-8df7-2e54a7208c1e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020778.5(ALPK3):c.3175C>T (p.Arg1059Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7709571"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0c88ebec-6e57-4d57-bf4d-86051f29b121","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0c88ebec-6e57-4d57-bf4d-86051f29b121_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","allele":{"id":"https://genegraph.clinicalgenome.org/r/e9da7027-c8d6-47f2-bc22-6b6986495d72","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020778.5(ALPK3):c.3436dup (p.Glu1146GlyfsTer12)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7709628"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/11a8672b-2994-437d-9d9b-9e229c55960c","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a8672b-2994-437d-9d9b-9e229c55960c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","allele":{"id":"https://genegraph.clinicalgenome.org/r/31476150-72a1-4ae2-90c9-8082015a2ae1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020778.5(ALPK3):c.4689G>A (p.Trp1563Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393365313"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d1a8bd8-9eb4-4945-a991-c637ef64b0e2_proband_segregation","type":"FamilyCosegregation","dc:description":"fewer than 4 segregations for autosomal dominant condition ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33302605","rdfs:label":"Family 10","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/9d1a8bd8-9eb4-4945-a991-c637ef64b0e2","type":"Family","rdfs:label":"Family 10","member":{"id":"https://genegraph.clinicalgenome.org/r/29d2c6de-97da-4ceb-a9fb-7f6bd6fb69fe","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33302605","rdfs:label":" IV-1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5dba9249-f84b-43e4-8f0b-d1cf744bca52"},"detectionMethod":"NGS - 60 genes associated with cardiomyopathy (Table 1); Trio-WES","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"single episode of syncope at 14yo, represented at 24yo with renal disease and HCM; LVEF of 50% without any signs of outflow obstruction","phenotypes":["obo:HP_0001670","obo:HP_0001712"],"secondTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b5b7f0d1-a92b-43a1-866a-100559204f22_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Proband's mother dx with HCM at 42yo, grandfather with HCM dx at 54yo and sudden cardiac death, brother genotype + but unaffected; brother of materanl grandfather deceased suddenly at 56yo w/o previous cardiac complications","phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0001638","proband":{"id":"https://genegraph.clinicalgenome.org/r/29d2c6de-97da-4ceb-a9fb-7f6bd6fb69fe"}},{"id":"https://genegraph.clinicalgenome.org/r/6d3e587a-689a-4f18-8a24-6e64c51e0661_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","rdfs:label":"Lopes B","family":{"id":"https://genegraph.clinicalgenome.org/r/6d3e587a-689a-4f18-8a24-6e64c51e0661","type":"Family","rdfs:label":"Lopes B","member":{"id":"https://genegraph.clinicalgenome.org/r/3bde6cf6-dfe3-4321-a5d6-8bcdd1dba687","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","rdfs:label":"B1","allele":{"id":"https://genegraph.clinicalgenome.org/r/31476150-72a1-4ae2-90c9-8082015a2ae1"},"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/11a8672b-2994-437d-9d9b-9e229c55960c_variant_evidence_item"}}},"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/3bde6cf6-dfe3-4321-a5d6-8bcdd1dba687"},"publishedLodScore":0.5771392},{"id":"https://genegraph.clinicalgenome.org/r/a75bc9d0-e7c3-4e20-b3a3-7beaf6733134_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191771","rdfs:label":"Cheawsamoot et al. Family","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/a75bc9d0-e7c3-4e20-b3a3-7beaf6733134","type":"Family","rdfs:label":"Cheawsamoot et al. Family","member":{"id":"https://genegraph.clinicalgenome.org/r/b662cf1b-fef3-465e-bc93-63301f0258de","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191771","rdfs:label":"Proband IV-1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/984ab8ca-c39b-465c-a03d-2024b0152e09","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020778.5(ALPK3):c.1417del (p.Gln473fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7709182"}},"detectionMethod":"WES; variant confirmed by Sanger sequencing","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"dx from screening echo; cardiac MRI showed mixed apical form of HCM; ECH showed LVH with T-wave inversion in multiple inferior and precordial leads","phenotypes":"obo:HP_0001639","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/09876ca5-155b-4780-9500-7896ecfbf508_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191771","allele":{"id":"https://genegraph.clinicalgenome.org/r/984ab8ca-c39b-465c-a03d-2024b0152e09"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"adult-onset HCM; proband's mother (III-7) dx with apical HCM at 48yo - she developed afib and died due to heart failure at 68yo, postmortem heart tissue showed marked hypertrophy and cardiomyocyte disarray\n\nMixed apical HCM was seen in 5 of the 7 affected individuals, 4 of whom also had right ventricular involvement; max left ventricular wall thickness = 15-27mm; 2 of the affected individuals reported to be asymptomatic","phenotypePositiveAllelePositive":7,"phenotypes":"obo:HP_0001639","proband":{"id":"https://genegraph.clinicalgenome.org/r/b662cf1b-fef3-465e-bc93-63301f0258de"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/03fcd7af-9c90-410c-bce3-2e0db69ab633_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","rdfs:label":"Lopes A","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/03fcd7af-9c90-410c-bce3-2e0db69ab633","type":"Family","rdfs:label":"Lopes A","member":{"id":"https://genegraph.clinicalgenome.org/r/15049322-9837-40c3-92b5-95da73754c3b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34263907","rdfs:label":"A1","allele":{"id":"https://genegraph.clinicalgenome.org/r/e9da7027-c8d6-47f2-bc22-6b6986495d72"},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0c88ebec-6e57-4d57-bf4d-86051f29b121_variant_evidence_item"}}},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/15049322-9837-40c3-92b5-95da73754c3b"},"publishedLodScore":0.0775649}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c86bf220-3e6c-4b6c-82d7-7e8e13ef37cc","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c86bf220-3e6c-4b6c-82d7-7e8e13ef37cc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30046096","allele":{"id":"https://genegraph.clinicalgenome.org/r/ce8180d9-c726-452d-bb03-3efc481ae7e9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020778.5(ALPK3):c.926_927del (p.Lys309ArgfsTer12)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499306950"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/09876ca5-155b-4780-9500-7896ecfbf508","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09876ca5-155b-4780-9500-7896ecfbf508_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a155f39-d7ee-4159-bc0c-df91aae2d1e6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1aad2a0c-0513-49e5-a1dd-5f3061dd321b","type":"Finding","dc:description":"Showed that ALPK3/ Midori is expressed exclusively in the fetal heart, and within the heart and skeletal muscle of adult mice by Northern blot. Characterized Midori expression in mouse embryos, found initial expression in the cardiac crescent at 7.5dpc and continued during heart development to 10.5 dpc. Showed exclusive expression in the nucleus of transiently transfected COS cells, using tagged-Midori.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11418590","rdfs:label":"Hosoda Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0d34165a-dd9b-4f9d-9321-2163926176ac","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d04d2ba3-470a-4099-a57c-38d1f94eca64","type":"Finding","dc:description":"Using reporter hPSC tagged for ALPK3 under immunofluorescence microscopy showed ALPK3 localized to the M-band demonstrated by;\n interdigitation with ACTN2 and \ncolocalization with OBSCN\nIt’s position between the two A-bands of the sarcomere (MYBPC3)\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39196058","rdfs:label":"McNamara Protein Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/725adecc-7b79-4b8e-9963-20e3a6313026","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1c06db8-d877-45c4-b8c4-cafdc4cea3aa","type":"Finding","dc:description":"ALPK3 is critical for the phosphorylation of sarcomeric & protein quality control proteins\ni.e critical for the 9 definitive sarcomereic HCM genes ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39196058","rdfs:label":"Phosphoroteomic profile of WT & ALPK3mut CMs","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/abb492b0-031c-4bb6-8cc6-d0e21e36b9cd","type":"EvidenceLine","dc:description":"Provides initial evidence of the importance of ALPK3 to heart development, by both in vitro and in vivo methods. Designated ALPK3 as Midori (for myocytic induction/differentiation originator. It contains 1 Ig-like domains, several NLS, and ATP/GTP-binding domain, and a Kringle-like domain. Note: If Midori/ ALPK3 can autoregulate it's expression, it gives validity to potential dominant negative isoforms perturbing function.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f80b3a0a-fa00-4b69-9890-c3a5033ec90c","type":"Finding","dc:description":"Provides initial evidence of the importance of ALPK3 to heart development, by both in vitro and in vivo methods. Designated ALPK3 as Midori (for myocytic induction/differentiation originator. It contains 1 Ig-like domains, several NLS, and ATP/GTP-binding domain, and a Kringle-like domain. Note: If Midori/ ALPK3 can autoregulate it's expression, it gives validity to potential dominant negative isoforms perturbing function.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11418590","rdfs:label":"Hosoda Biochemical Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/314178db-956b-4009-a567-aa797436d82c","type":"EvidenceLine","dc:description":"Scored as zero, as complete inhibition of Midori was used to show perturbed cell differentiation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7038aa07-e4a8-4853-87fb-c662facde724","type":"FunctionalAlteration","dc:description":"Block of Midori expression in P19CL6 cells by antisense oligo expression of Midori, perturbed Me2SO mediated differentiation (the cells also did not beat). MHC staining was also decreased in cells expression the antisense to Midori, and reduced expression was confirmed by western blot.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11418590","rdfs:label":"Hosoda Functional Alteration"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ace85164-0b70-46a2-ac6b-253088f4514d_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d39969a-398b-4f1c-a35f-98139e60d87d","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/859ea1eb-09bc-44cf-a9f6-5e96d2af7706","type":"Finding","dc:description":"Alpk3+/– heterozygote mice had normal contractile function, fertility, and survival, but developed significant ventricular hypertrophy beyond 1 year of age (Figure 3E, mean LV posterior wall thick- ness age 51 to 90 weeks: Alpk3+/– (n=20)=0.95 mm versus Wt (n=16)=0.77 mm; P=7.0×10-10) \n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36321451","rdfs:label":"Argarwal mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Strong","sequence":9841,"specifiedBy":"GeneValidityCriteria9","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/uzSsqnzjHvA","type":"GeneValidityProposition","disease":"obo:MONDO_0005045","gene":"hgnc:17574","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ace85164-0b70-46a2-ac6b-253088f4514d-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}